St Louis, MO Clinical Trials Report — May 2026

For St. Louis residents considering participation in clinical research, May 2026 brings important deadlines for existing trials and exciting new opportunities to contribute to medical science. Across St. Louis, MO, a total of 1,338 clinical trials are currently recruiting across 411 research facilities, offering diverse avenues for participation.

A significant number of trials are nearing their enrollment deadlines, making prompt action essential for interested individuals. A total of 65 trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 11 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Alzheimer disease (3 trials)
• Solid tumor (3 trials)
• Heart failure (2 trials)
• Advanced solid tumor (2 trials)
• Chronic kidney diseases (2 trials)
• Quality of life (2 trials)
• Alfi syndrome (1 trial)
• Anthocyanins (1 trial)
• 9p partial monosomy syndrome (1 trial)
• Amyotrophic lateral sclerosis (1 trial)

New Research Opportunities Emerge

This month, St. Louis saw the opening of 14 new clinical trials. This is a slight decrease from the 15 trials that launched in April 2026, and the 19 that opened in March 2026, but still represents a steady flow of new research. These new studies offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

May brings several high-profile new trials to St. Louis, MO, including significant Phase 2 and Phase 3 studies from major sponsors:

• Novo Nordisk A/S is initiating a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
• Another significant Phase 3 trial from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This study involves 2,500 participants and investigates the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• AstraZeneca is sponsoring NCT07608354, "A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM." This Phase 2, double-blind, placebo-controlled study will involve 326 participants to assess a new treatment combination for Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
• A study sponsored by RAI Services Company, NCT07598136, "A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers," is recruiting 1,280 participants to assess the impact of electronic nicotine delivery system (ENDS) flavor availability on smoking abstinence.
• The University of California, San Francisco is leading NCT07579364, "Outcomes Tracking in Unilateral Vocal Fold Paralysis (UVFP) and Atrophy After Medialization Laryngeal Surgery," an observational study with 500 participants to learn about the long-term outcomes of Laryngeal Framework Surgery.
• Another notable study, NCT07613398, "An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function," sponsored by Matthias Stuber, aims to evaluate a new cardiac MRI technique in 300 participants.

New trials this month are exploring a range of conditions, with the most frequent being prostate cancer (2 trials) and obesity (2 trials). Other conditions include AML, adult recurrent; cardiac diseases; congenital heart disease (CHD); depression; heart failure; hepatic cirrhosis; and liver fibrosis. Drug trials account for the largest share of new studies, with 10 new drug trials, followed by 6 "other" types of studies, and 1 each for biological, device, diagnostic test, and procedure trials.

Industry sponsors are driving the majority of new research this month, with 9 new industry-sponsored trials compared to 5 academic or other sponsored studies. Notable industry sponsors include AstraZeneca and Novo Nordisk A/S, each sponsoring 2 new trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are opportunities to contribute to research. Of the 14 new trials launched this month, 1 is actively seeking healthy volunteers. Across St. Louis, a total of 110 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

St. Louis's Leading Research Facilities

St. Louis is home to prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in